How cells communicate during development and regeneration is a critical question. One mechanism of intercellular communication is via exosomes, extracellular vesicles that originate by the fusion of multivesicular endosomes with the plasma membrane [1] [2] [3] [4] [5] [6] [7] [8] . To model exosome-based intercellular communication, we used Madin-Darby canine kidney (MDCK) cell cysts grown in 3D gels of extracellular matrix, which form tubules in response to hepatocyte growth factor (HGF). We report that GPRC5B, an orphan G protein coupled receptor, is in exosomes produced by HGF-treated cysts and released into the cyst lumen. Exosomal GPRC5B is taken up by nearby cells and together with HGF promotes extracellular signal-regulated kinase 1/2 (ERK1/2) activation and tubulogenesis, even under conditions where tubulogenesis would otherwise not occur. Recovery from injury, such as acute kidney injury (AKI), often recapitulates developmental processes. Here, we show that GPRC5B is elevated in urinary exosomes from patients with AKI. Our results elucidate how GPRC5B is carried by exosomes and augments HGF-induced morphogenesis. The unexpected role of exosomes in transporting GPRC5B between cells during morphogenesis and the ability of GPRC5B to predict the disease state of AKI elucidate a novel mechanism for intercellular communication during development and repair.
As a model system to study mammalian organogenesis, we grow Madin-Darby canine kidney (MDCK) cells in 3D organotypic culture in thick gels of extracellular matrix (ECM) so that the cells form cysts with a central lumen lined by a monolayer of polarized epithelial cells. When stimulated with HGF, these cells proliferate and undergo tubulogenesis, which is reminiscent of tubulogenesis found in several developmental processes. We previously identified genes that are regulated during hepatocyte growth factor (HGF)-induced tubulogenesis [9] . We focused now on GPRC5B, which is highly upregulated early in in vitro tubulogenesis and is particularly highly expressed in the ureteric bud during embryonic kidney development [10] . GPRC5B is a poorly characterized G protein coupled receptor, which was originally cloned as a retinoic-acid-induced gene (also called RAIG-2) [11] . It has been implicated in neuronal cell fate determination [12] and obesity-associated inflammation [13] . However, its molecular signaling mechanisms and the identity of any potential ligand activator or interacting partners, with the exception of the Fyn kinase, remain largely unknown. We noticed that w9% of the genes that we previously identified as undergoing temporal regulation during in vitro tubulogenesis, including GPRC5B, are present in urinary exosomes (data not shown) when compared with exosome databases [14, 15] , suggesting a potential role for exosomes in tubulogenesis. We first confirmed by quantitative PCR that GPRC5B was induced in MDCK cells that have been exposed to conditioned medium from MRC5 cells, a fibroblast cell line providing tubulogenic factors, including HGF ( Figure 1A ). HGF alone can cause tubulogenesis, although not as well as MRC5 conditioned medium, and we found that HGF alone was also sufficient for GPRC5B induction.
Induction of GPRC5B was blocked by U0126, a MEK inhibitor, indicating the induction is downstream of the MAP kinase pathway, a key signaling pathway in tubulogenesis [16] (Figure 1A ). Next, we tested whether GPRC5B induction is required for tubulogenesis in MDCK cysts grown in collagen. Two functional small hairpin RNAs (shRNAs) targeting GPRC5B significantly decreased the fraction of cysts making tubules upon HGF treatment, compared to control cells expressing an irrelevant shRNA ( Figures 1B and 1C) . Additionally, the average length of the tubules that did form was significantly shorter in shRNA-mediated knockdown cells (Figure 1D ; Figure S1A available online), suggesting that GPRC5B controls both the number and length of tubules.
Because GPRC5B is required for tubulogenesis, we tested whether exogenous expression of GPRC5B fused to green fluorescent protein (GPRC5B-GFP) could confer outward growth to MDCK cells grown in Matrigel, in which (unlike collagen I gels) wild-type (WT) MDCK cysts are unable to invade in response to HGF [17] . This provides a more stringent model to examine cell movement and tubulogenesis. Unexpectedly, cysts expressing GPRC5B-GFP invaded Matrigel as tubules or scattered cells upon HGF treatment (referred to here as outward growth), while control cysts expressing GFP alone showed virtually no outward growth into the surrounding Matrigel. Instead, cells accumulated in the lumen, indicating the lack of outward growth is not due to the absence of HGF signaling ( Figure 1E ). We further examined cysts that expressed GPRC5B-GFP at various subthreshold levels and found that, in response to HGF, high expression resulted in outward growth, while low expression resulted in accumulation of cells in the lumen (Figure S1B ), suggesting that the expression level of GPRC5B determines outward growth. Indeed, when cells were sorted on the basis of GFP fluorescence using fluorescence-activated cell sorting, cysts formed from cells with the highest 10% of expression level of GPRC5B-GFP had significantly more outward growth in response to HGF, compared with those from the lowest 10% ( Figure 1F ). Finally, shRNA directed against GPRC5B also decreased outward growth induced by GPRC5B-GFP (Figure 1G) . The observed outgrowth is specific for GPRC5B, because overexpression of CD82, an irrelevant exosome protein [18] , did not exert a similar effect ( Figure S1C ). These data *Correspondence: keith.mostov@ucsf.edu suggest that GPRC5B induced by HGF promotes outward growth of cysts.
We found GPRC5B-GFP is localized at the apical membrane and/or in the intraluminal space of cysts (Figure 2A ), suggesting that GPRC5B may be exported through extracellular vesicles from the apical surface. Differential centrifugation of conditioned medium in contact with the apical surface of monolayer-grown MDCK cells was performed to fractionate extracellular vesicles into fractions enriched in microvesicles (released by blebbing of the plasma membrane) or exosomes (released by fusion of multivesicular endosomes with the plasma membrane) ( Figure 2B ). Electron micrographs confirmed that each fraction contained a majority of vesicles that are consistent with the known diameters of microvesicles (111.5 6 45.6 nm) and exosomes (63.0 6 19.4 nm) [19, 20] . Marker analysis with phosphohistone and cytochrome c showed that the exosome fraction was not contaminated with apoptotic bodies. Hsp70, a known exosome marker in MDCK, was present in the exosome fraction (not shown). Thus, released GPRC5B-GFP was primarily on exosomes.
The release of exosomes in other systems has been shown to depend on the small GTPases Rab7, Rab11, Rab27, and Rab35 [21] [22] [23] [24] . We tested whether these colocalize with GPRC5B-GFP. Rab35 had the highest colocalization with GPRC5B-GFP ( Figure S2 ), though the possibility of involvement of the other Rabs remains. We grew MDCK cells as a monolayer and tested the effect on release of GPRC5B-GFP in exosomes of constitutively active (QL), dominant-negative (SN), and wildtype (WT) alleles of Rab35 fused to the fluorescent protein mCherry ( Figure 2C ). In contrast to Rab35-WT and Rab35-QL, expression of Rab35-SN decreased release of GPRC5B-GFP. These data suggest GPRC5B is apically released in exosomes via intracellular trafficking controlled by Rab35.
The cis-acting signals that direct proteins into exosomes are poorly understood [25] . We used a series of truncation mutations in GPRC5B-GFP, to determine the signal within GPRC5B that directs the protein into exosomes ( Figure S3A , left). Removal of the entire 101-amino-acid (aa) cytoplasmic, C-terminal tail (D101) spanning residues 286-384, abolished exosomal release of GPRC5B-GFP. This is unlikely due to misfolding, as D101 reached the cell surface. In sharp contrast, removal of the C-terminal 80 aa did not block exosomal release. Using alanine scanning, a triple alanine mutant, 286-288A, showed impairment of release of GPRC5B-GFP comparable to D101, without loss of surface expression ( Figure 3A ; Figure S3A ). In addition, 286-288A accumulated in small vesicles, possibly endosomes, which were much more prominent compared with WT GPRC5B-GFP ( Figure 3B ). The correlation of reduction in exosomal release with intracellular vesicular accumulation suggests potential interference in endosome traffic.
We next analyzed budding of GPRC5B-GFP into endosomes. Because GPCRs often use ubiquitination of cytoplasmic-exposed lysines for intraendosomal transport [26] , we mutated all such lysines in GPRC5B-GFP to arginine (iKRs), which had reduced exosomal release compared to WT GPRC5B-GFP ( Figure 3A ; Figure S3B ). To improve visualization of the location of GPRC5B-GFP, we enlarged endosomes by overexpressing constitutively active Rab5(QL) [27] ( Figure 3C ; Figure S2 ). WT GPRC5B-GFP was diffusely distributed throughout the lumen of enlarged endosomes, presumably on intraluminal vesicles that are below resolution of the microscope. In contrast, iKRs and 286-288A often appeared as aggregates on the limiting membrane, rather than diffuse in the lumen ( Figure 3C ). 286-288A was often in a single aggregate on the membrane. Quantitation showed a significant reduction of 286-288A in the lumen and redistribution to the limiting membrane ( Figure 3D ). These data suggest that the cytoplasmic lysines and juxtamembrane residues 286-288 determine transport of GPRC5B into the lumen of the endosome, presumably by budding of vesicles into the lumen of the endosome, thereby leading to its eventual exosomal release. Finally, cysts expressing 286-288A exhibited significantly decreased outward growth ( Figure 4A ), providing a direct link between endosomal release of GPRC5B and its biological function.
Though little is known about how exosomes are transferred to target cells [28, 29] , several membrane-anchored ligands involved in development, such as amphiregulin and Wnt proteins, have been shown to be released in exosomes and act on target cells [3, 8] . Receptor tyrosine kinase c-Met is released from melanoma cells via exosomes and causes bone marrow cells to have an increased level of c-Met [6] , though physical transfer of c-Met between these cell types has not been shown. We therefore tested whether an exosomally released receptor, GPRC5B-GFP, is taken up by other cells and promotes outward growth. We generated mosaic cysts with two populations of MDCK cells: target cells expressed cytoplasmic red fluorescence protein (RFP) but were otherwise WT, and donor cells expressed GPRC5B-GFP. Confocal microscopy confirmed that when grown in mosaic cysts, GPRC5B-GFP was observed at the apical membranes of both cell types ( Figure S4A ) and in the interior of the RFP-expressing cells that were not in contact with cells producing GPRC5B-GFP ( Figure 4B ). Furthermore when exosomes purified from conditioned medium of cells expressing GPRC5B-GFP were added to the exterior of cysts comprised of WT MDCK, the GPRC5B-GFP was internalized into the WT MDCK ( Figure S4B) . A similar process of uptake from the basolateral surface may occur when polarity is disrupted due to wounding, HGF stimulation, or cancer [30] .
Next, we asked whether exogenously added exosomes from cells expressing GPRC5B-GFP could induce outward growth in WT MDCK cysts grown in Matrigel ( Figure 4C ). Upon HGF treatment, cysts underwent outward growth when exosomes purified from cells expressing GPRC5B-GFP was added, while exosomes from cells expressing only GFP, or exosomedepleted medium from cells expressing GPRC5B-GFP, did not cause outward growth.
The MAP kinase pathway is downstream of c-Met and is essential for tubulogenesis [16, 31] . We tested whether GPRC5B-GFP modulates the MAP kinase pathway as determined by phosphorylation status of ERK1/2 in lysates from cysts. Upon HGF stimulation, ERK1/2 activation was elevated in cysts expressing GPRC5B-GFP, compared with cysts expressing GFP alone ( Figure 4D ). We next tested whether transfer of exosomes containing GPRC5B-GFP was responsible for the increased ERK1/2 activation. We grew MDCK cells expressing either GFP or GPRC5B-GFP as monolayers and collected the conditioned medium. Exosomes were purified from this by centrifugation, resuspended in culture medium, and added to WT MDCK cysts, which were assayed for ERK1/2 activation. (As an additional control, resuspended exosomes from the GPRC5B-GFP conditioned medium were recentrifuged to give an ''exosome depleted'' condition.) Exosomes containing GPRC5B-GFP potentiated ERK1/2 activation in recipient cysts of WT MDCK cells ( Figure 4E ), suggesting that GPRC5B augments ERK1/2 activation in recipient cells through exosomal transfer. In the light of our findings, we propose that induced GPRC5B potentiates MAP kinase activation in HGF-stimulated cells. Hyperactivation of MAP kinase signaling leads to cell scattering rather than tubulogenesis. Exosomal release of GPRC5B likely acts to (1) downregulate and avoid inappropriate overactivation of ERK1/2 in exosome releasing cells and (2) laterally propagate ERK1/2 activation in nearby exosome recipient cells. Thus, exosomes are proposed to be part of a signaling mechanism that controls a collective response to HGF for invasive growth.
Developmental processes, such as tubulogenesis, are often recapitulated during wound repair and regeneration. Because our data suggest that exosomes can carry a signal from donor cells to recipient cells during tubulogenesis, we tested whether GPRC5B in exosomes from MDCK cells stimulated with MRC5-conditioned medium can increase collective cell migration in a model of wound healing. In this assay, MDCK cells are grown as a monolayer on a solid support. A silicone rubber barrier forms a rectangular, cell-free gap, 500 6 50 mm wide, in the middle of the monolayer. When the barrier is removed, cells on both sides begin to migrate to fill in the cell-free region. This is similar to a scratch wound assay, but more reproducible. The monolayer showed markedly increased migration when incubated with isolated exosomes from MDCK cells stimulated with MRC5-conditioned medium ( Figure 4F ; Figure S4C ). Importantly, this enhanced migration was significantly decreased when exosomes were isolated from MDCK cells expressing shRNAs targeting GPRC5B, suggesting endogenous GPRC5B transferred via exosomes stimulates migration.
Recovery from injury and regeneration often recapitulates developmental processes, although the role of exosomes in injury repair has been little explored. Such processes are very important clinically. For instance, acute kidney injury (AKI), where the epithelial cells lining the tubules of the kidney are injured or die, is a major source of morbidity and mortality in hospitalized patients, associated with upward of 10 billion dollars in costs each year in the United States [32] . Furthermore, the consequences of incomplete recovery leading to chronic kidney disease are a major clinical concern that has only recently been appreciated [33, 34] . So far, methods to predict which patients will suffer long-term sequelae from AKI are lacking. The involvement of exosome-mediated transfer of GPRC5B in tubulogenesis and wound healing in culture led us to examine whether this protein is involved in AKI. HGF and c-Met play an important role in AKI. In AKI, both serum HGF and renal c-Met expression are increased, and c-Met is activated concomitantly [35] [36] [37] . Indeed, HGF enhances renal repair in animal models of AKI [38, 39] . First, we asked where GPRC5B was expressed in human kidney. Marker analysis showed GPRC5B was present predominantly in collecting ducts, to a much lesser extent in proximal tubules, and, rarely, in the loop of Henle ( Figure S4D ). To determine the involvement of GPRC5B in AKI, we isolated exosomes from the urine of patients who met predefined criteria for AKI [40] . Urine was collected from critically ill human subjects who met inclusion criteria for a prospective cohort study under a protocol that was reviewed and approved by the University of California, San Francisco Institutional Review Board. Immunoblotting showed a significant increase of urinary GPRC5B in patients with AKI at day 1 ( Figure 4G ). Collectively, these data suggest urinary exosomal GPRC5B might potentially serve as a muchneeded biomarker for AKI.
Together, our study illuminates the surprising roles of exosomes and GPRC5B in development and regeneration and is an important step in understanding and improving the limited regenerative capacity of the kidney.
Experimental Procedures Invasive Growth Assay in Extracellular Matrices
In vitro tubule formation assays were previously described [9] . Briefly, for the HGF-induced tubule formation assay, 4-day-old cysts overlaid on Matrigel and grown in 2% Matrigel were simulated for 48 or 78 hr with 12.5 ng/ml recombinant HGF, together with collagen I as supporting 3D matrix. For outward growth in nonpermissive ECM microenvironment, 2% Matrigel was used as supporting matrix when 4-day-old cysts were stimulated with 12.5 ng/ml HGF. For counting tubule length, digital images were taken from the center of culture chamber well with a DinoXcope microscope (Dino-Lite). The distance between the leading edge of tubule and cyst wall was marked with Freehand selection and was then measured using ImageJ. Other methods are described in Supplemental Experimental Procedures. (F) Wound healing due to endogenous GRPC5B carried in exosomes. MRC5 cells were grown in serum-free medium and the resultant conditioned medium was centrifuged to remove any exosomes. This MRC5 conditioned medium was then added to MDCK cells grown as monolayers and expressing either shRNA for GPRC5B (GPRC5B KD) or a scrambled control (SCR KD). The conditioned medium from these MDCK cells was then subjected to centrifugation to purify exosomes. The exosomes, either GPRC5B KD or SCR KD, were then added to a second set of cultures of WT MDCK cells grown as monolayers; these cultures had an ibidi silicone barrier to prevent growth in a gap region. The silicone barrier was removed immediately before addition of the purified exosomes. Migration was measured as the area of the gap that was covered by migrating cells over 6 hr. Values are the mean 6 SE of three independent experiments. (G) Quantification of GPRC5B in human urinary exosomes. Urine was collected at the first day after critically ill subjects met predefined criteria for AKI and provided informed consent. Samples were processed as blinded samples to measure GPRC5B in exosomes using immunoblotting. See also Figure S4 .
